An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin and TB-500. The panel turned down emideltide. HIMS stock rose as shares jumped overnight after the committee backed four peptides. Bachem shares held steady after the vote. A recent study indicated peptides may aid treatment of antibiotic-resistant bacteria. Meanwhile, Robert F. Kennedy Jr. pushed for broader availability to controversial peptides, calling for loosened oversight. The vote reflects a broader shift in how regulators view custom-mixed peptide therapies, which have drawn growing interest from users seeking alternatives to conventional drugs. Researchers say peptide treatments could alter approaches to resistant infections, though concerns about safety persist. The committee's endorsement of six peptides opens the door for more broad prescribing, even as skeptics warn of limited evidence. Industry analysts note that peptide-focused companies may see greater investor attention following the panel's decision. The rejection of emideltide, meanwhile, signals the FDA's cautious stance on particular peptide candidates.